WO2009148059A1 - クリーム状o/w型乳化組成物及びその製造方法 - Google Patents
クリーム状o/w型乳化組成物及びその製造方法 Download PDFInfo
- Publication number
- WO2009148059A1 WO2009148059A1 PCT/JP2009/060086 JP2009060086W WO2009148059A1 WO 2009148059 A1 WO2009148059 A1 WO 2009148059A1 JP 2009060086 W JP2009060086 W JP 2009060086W WO 2009148059 A1 WO2009148059 A1 WO 2009148059A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- adenosine
- fatty acid
- component
- acid ester
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to a creamy O / W emulsion composition containing adenosine phosphate and having excellent emulsification stability and usability, and a method for producing the same.
- adenosine phosphates Various physiological functions are known for adenosine phosphates.
- adenosine phosphates are added to the composition. It is necessary to blend at a ratio above a certain concentration.
- adenosine phosphate which is an electrolyte, has an electrolyte-specific property of reducing the strength of the oil-water interface film in the emulsion composition. Therefore, when an emulsion composition containing adenosine phosphate ester (especially an O / W emulsion composition) is produced, the emulsion particles coalesce to cause separation of the water phase and the oil phase, and oil floating. It is known to be easy. In addition, even if there is no change in appearance, the emulsification system itself may deteriorate with time due to the influence of adenosine phosphate, resulting in a rapid viscosity drop.
- an O / W emulsion composition containing adenosine phosphate for example, polyglycerol fatty acid ester, acrylic acid alkyl methacrylate copolymer
- alkanoyl lactic acid or a salt thereof was blended (see Patent Document 1).
- an electric repulsion action by an ionic emulsifier such as alkanoyl lactic acid was utilized.
- a composition containing an ionic emulsifier exhibits stability in an O / W type emulsion composition having a high liquid fluidity such as an emulsion, but it alone in a creamy O / W type emulsion composition having viscosity. Therefore, the stabilization of the system cannot be satisfied. Therefore, an O / W type emulsification system in which solid amphiphilic lipids such as higher fatty acids and higher alcohols are blended with ionic emulsifiers has been obtained.
- the stability of the composition is impaired due to the destabilization of the system by the electrolyte, and the viscosity cannot be maintained for a long time.
- separation of the composition due to a change in temperature is promoted, and thus it has been difficult to obtain a stable composition having a high viscosity and containing an electrolyte. .
- the main object of the present invention is to provide a creamy O / W emulsion composition containing an adenosine phosphate ester which exhibits excellent emulsification stability even under high temperature conditions or storage conditions where temperature changes are severe. Objective.
- an emulsion composition containing adenosine phosphate ester, polyglycerin fatty acid ester, acrylic acid alkyl methacrylate copolymer, amphiphilic lipid and polyhydric alcohol By adding a self-emulsifying glycerin fatty acid ester to the product, the emulsifying power is remarkably improved, and as a result, a composition capable of maintaining high viscosity and emulsification stability while containing an electrolyte can be produced. I found it.
- the present invention provides the following creamy O / W emulsion composition and a method for producing the same, and an emulsion stabilization method for a cream O / W emulsion composition containing adenosine phosphate.
- Item 1 A creamy O / W emulsion composition containing components (A) to (F) in the following proportion in the total amount of the emulsion composition and having a viscosity at 20 ° C.
- A at least one adenosine phosphate selected from the group consisting of adenosine-3 ′, 5′-cyclic phosphate, adenosine monophosphate, adenosine diphosphate, adenosine triphosphate, and salts thereof 0.1% by weight or more;
- B 0.5-6% by weight of polyglycerol fatty acid ester;
- C 0.05 to 0.7% by weight of an alkyl methacrylate methacrylate copolymer;
- D 0.5-10% by weight of amphiphilic lipid;
- E 0.5-20% by weight of polyhydric alcohol; and
- F 0.3 to 5% by weight of self-emulsifying glycerin fatty acid ester.
- Item 2. The creamy O / W emulsion composition according to Item 1, wherein the component (B) is an ester of a fatty acid having 12 to 36 carbon atoms and a polyglycerol having a polymerization degree of 6 or more.
- Item 3. Item 3.
- the component (D) contains at least one selected from the group consisting of higher fatty acids, higher alcohols, monoalkyl glyceryl ethers, ceramides, sugar ceramides, glycolipids, lecithins, lecithin derivatives, and structural analogs thereof.
- Item 5. The creamy O / W emulsion composition according to any one of Items 1 to 4, wherein the component (E) is a trivalent polyhydric alcohol.
- Item 6. Item 6.
- Item 7. Item 7.
- Item 8. Item 8.
- Item 9. Item 9. The creamy O / W emulsion composition according to any one of Items 1 to 8, which is a skin cosmetic, a skin external medicine or a quasi drug.
- Item 10. Item 9. Use of the creamy O / W emulsion composition according to any one of Items 1 to 8 for producing a skin cosmetic, a dermatological drug, or a quasi-drug for external use.
- step 1) to 3 Including the following steps 1) to 3), (A) 0.1% by weight or more of adenosine phosphate, (B) 0.5 to 6% by weight of polyglycerin fatty acid ester, (C) ) 0.05 to 0.7% by weight of alkyl methacrylate copolymer, (D) 0.5 to 10% by weight of amphiphilic lipid, (E) 0.5 to 20% by weight of polyhydric alcohol And (F) a self-emulsifying glycerin fatty acid ester in a proportion of 0.3 to 5% by weight and a viscosity at 20 ° C.
- Preparation method 1) A step of preparing a non-aqueous emulsion using a composition comprising (B) polyglycerin fatty acid ester, (D) amphiphilic lipid, (E) polyhydric alcohol and (F) self-emulsifying glycerin fatty acid ester, 2) (A) at least one adenosine phosphate selected from the group consisting of adenosine-3 ′, 5′-cyclic phosphate, adenosine monophosphate, adenosine diphosphate, adenosine triphosphate, and salts thereof
- Item 12. Including the following steps 1) to 3), (A) 0.1% by weight or more of adenosine phosphate, (B) 0.5 to 6% by weight of polyglycerin fatty acid ester, (C) ) 0.05 to 0.7% by weight of alkyl methacrylate copolymer, (D) 0.5 to 10% by weight of amphiphilic lipid, (E) 0.5 to 20% by weight of polyhydric alcohol And (F) a cream containing adenosine phosphate, wherein the self-emulsifying glycerin fatty acid ester is contained in a proportion of 0.3 to 5% by weight, and the viscosity at 20 ° C. is 5000 to 60000 cps.
- Emulsification stabilization method of the O / W emulsion composition 1) A step of preparing a non-aqueous emulsion using a composition comprising (B) polyglycerin fatty acid ester, (D) amphiphilic lipid, (E) polyhydric alcohol and (F) self-emulsifying glycerin fatty acid ester, 2) (A) at least one adenosine phosphate selected from the group consisting of adenosine-3 ′, 5′-cyclic phosphate, adenosine monophosphate, adenosine diphosphate, adenosine triphosphate, and salts thereof
- long-term emulsification stability which contains adenosine phosphate ester, which is generally considered difficult to emulsify, is suppressed even under high temperature and severe temperature change, separation, oil floating, gel formation, etc. It is possible to provide a creamy O / W emulsified composition excellent in water resistance. .
- the creamy O / W emulsion composition of the present invention can contain a large amount of adenosine phosphate in a stable state, cosmetics or skin external preparations containing adenosine phosphate as an active ingredient (pharmaceuticals or quasi-drugs) Etc.).
- an O / W emulsion composition containing adenosine monophosphate (AMP) or a salt thereof can effectively exhibit the moisturizing action and the skin turnover promoting action of the substance, and prevent skin wrinkles. It is useful as a cosmetic or an external preparation for skin that is effective in preventing skin aging and making the skin beautiful.
- the present invention not only is the long-term emulsion stability excellent, but also adenosine phosphate ester, polyglycerin fatty acid ester, amphiphilic lipid, alkyl acrylate methacrylate copolymer, polyhydric alcohol, self-emulsifying
- adenosine phosphate ester polyglycerin fatty acid ester
- amphiphilic lipid alkyl acrylate methacrylate copolymer
- polyhydric alcohol self-emulsifying
- the cream-like O / W emulsion composition of the present invention is particularly useful as an external preparation, for example, a skin cosmetic (including scalp cosmetic), a skin external medicine (including scalp), or a quasi-drug. Useful.
- the present invention provides a method for improving the emulsion stability of a creamy O / W emulsion composition containing a relatively large amount of adenosine phosphate. Therefore, according to the method of the present invention, creamy O / W type emulsification containing adenosine phosphate that can effectively utilize the action of adenosine phosphate having various physiological functions and can be effectively used. A composition can be obtained easily.
- Cream O / W Emulsion Composition The cream O / W emulsion composition of the present invention is characterized by containing a predetermined amount of the following components (A) to (F).
- A the configuration of the present invention will be described in detail.
- Adenosine phosphate used in the present invention is not particularly limited, but is preferably applied to the skin to exhibit physiological functions.
- it is an external preparation, particularly cosmetics or external use. What can be mix
- it is water-soluble or hydrophilic.
- adenosine phosphates include adenosine-3 ′, 5′-cyclic phosphate, adenosine monophosphate (AMP), adenosine diphosphate, adenosine triphosphate, and salts thereof, preferably adenosine- Examples thereof include 3 ′, 5′-cyclic phosphate, adenosine monophosphate, adenosine diphosphate, and salts thereof. These may be used alone or in any combination of two or more.
- the above-mentioned various salts include salts with alkali metals such as sodium and potassium; salts with alkaline earth metals such as calcium, magnesium and barium; salts with basic amino acids such as arginine and lysine; Examples thereof include salts with ammonium such as cyclohexylammonium; salts with alkanolamines such as monoisopropanolamine, diisopropanolamine and triisopropanolamine. Among these, a salt with an alkali metal is preferable.
- the component (A) used in the present invention is preferably adenosine monophosphate monosodium, adenosine monophosphate disodium, adenosine triphosphate monosodium, adenosine triphosphate disodium, adenosine triphosphate trisodium, adenosine -3 ', 5'-cyclic phosphoric acid and the like.
- Adenosine phosphate is phosphorylated in the cell and converted to ATP which is an energy source.
- the composition containing the adenosine phosphate can be absorbed percutaneously by applying the composition to a site where skin aging is a concern, and can promote intracellular ATP production. Is.
- An increase in intracellular ATP level activates skin cell metabolism and promotes cell cycle to promote skin turnover. By promoting the turnover of the skin, the old stratum corneum is discharged and new stratum corneum cells are supplied. As a result, the water retention environment is improved, the skin's flexibility and elasticity are improved, and the skin is smooth and dull. It becomes possible to guide.
- the ratio of the adenosine phosphate compounded in the emulsion composition of the present invention is not particularly limited as long as the amount of the adenosine phosphate ester exhibits a desired effect. Specifically, although it varies depending on the type of adenosine phosphate used, it is at least 0.1% by weight or more, preferably 0.5-7% by weight, more preferably 1-6% by weight per 100% by weight of the final emulsion composition. % Range.
- the polyglycerin fatty acid ester used in the present invention is not particularly specified, but is a fatty acid having 12 to 36 carbon atoms and a polyglycerol having a polymerization degree of 6 or more, particularly 6 to 10 Mention may be made of esters.
- Fatty acids that form esters with polyglycerol may be saturated, unsaturated, linear or branched fatty acids, specifically capric acid, lauric acid, isotridecanoic acid, myristic acid, palmitic acid, palmitoleic acid , Stearic acid, isostearic acid, oleic acid, linoleic acid, behenic acid or ricinoleic acid.
- polyglycerin fatty acid esters include hexaglyceryl monolaurate, hexaglyceryl monoisostearate, hexaglyceryl monomyristate, hexaglyceryl dioleate, hexaglyceryl dimyristate, hexaglyceryl dipalmitate, hexaglyceryl distearate, Hexaglyceryl dibehenate, hexaglyceryl trilaurate, hexaglyceryl trimyristate, hexaglyceryl tripalmitate, hexaglyceryl tristearate, hexaglyceryl tribehenate, hexaglyceryl tetralaurate, hexaglyceryl tetramyristate, tetra Hexaglyceryl palmitate, hexaglyceryl tetrastearate, hexaglyceryl
- polyglycerin fatty acid esters can be used alone or in any combination of two or more. Further, as the polyglycerin fatty acid ester, those having an HLB of 10 or more, particularly 10 to 15 can be preferably used. Such polyglycerin fatty acid ester is preferably used in an amount of 0.5 to 6% by weight, more preferably 1 to 5.5% by weight, per 100% by weight of the final emulsion composition. Can do.
- the alkyl methacrylate polymer used in the present invention is not particularly limited, but usually has an alkyl chain having 5 to 40 carbon atoms. Can be mentioned. Preferably, the alkyl chain has 10 to 30 carbon atoms. These can be conveniently used commercially available, and is not limited, but specifically, Carbopol (trademark) 1342 (manufactured by Lubrizol), Carbopol (trademark) ETD2020 (manufactured by Lubrizol), Examples include Pemulen (trademark) TR-1 (manufactured by Lubrizol), Pemulen TR-2 (manufactured by Lubrizol), and the like.
- alkyl methacrylate polymers can be used alone or in any combination of two or more.
- the alkyl methacrylate polymer is preferably used in an amount of 0.05 to 0.7% by weight, more preferably 0.1 to 0.6, per 100% by weight of the final emulsion composition. It is a percentage by weight.
- Amphiphilic lipids have both a “hydrophilic group” (hydrophilic functional group) and a “lipophilic group” (hydrophobic functional group) in one molecule and do not dissolve in water. Is a general term for solid lipids that tend to disperse.
- Component (D) is not particularly limited as long as it is pharmaceutically or cosmetically acceptable. Specifically, higher fatty acid, higher alcohol, monoalkyl glyceryl ether, sphingolipid, glycolipid, lecithin , Lecithin derivatives, and structural analogs thereof.
- higher fatty acids such as myristic acid, stearic acid, oleic acid, palmitic acid and behenic acid (14 to 22 carbon atoms); higher alcohols include octanol, myristyl alcohol, cetyl alcohol, cetostearyl alcohol, stearyl alcohol, behenyl alcohol, Linear or branched saturated or unsaturated alcohols (8 to 22 carbon atoms) such as isostearyl alcohol, cholesterol, phytosterol; chimyl alcohol, batyl alcohol (glyceryl monostearyl ether), ceralkyl alcohol, isostearyl glyceryl ether, Monoalkyl glyceryl ethers such as monodocosaglyceryl ether (alkyl carbon number 8-22); sphingolipids such as ceramide and phytosphingosine and glycosides thereof ( For example, sugar ceramide); glycolipid such as galactolipid, sulfolipid, glycosphingolipid; lecithin
- amphiphilic lipid selected from higher fatty acids, higher alcohols, monoalkyl glyceryl ethers, lecithins and lecithin derivatives as the component (D).
- amphiphilic lipids selected from higher fatty acids, higher alcohols, monoalkyl glyceryl ethers, lecithins and lecithin derivatives.
- the amphiphilic lipids may be used alone or in combination of two or more substances.
- the mixing ratio of the amphiphilic lipid varies depending on the dosage form and the like, but is preferably 0.5 to 10% by weight, more preferably 0.5 to 5% by weight, more preferably 100% by weight of the final emulsified composition.
- a preferred range is 0.5 to 3% by weight. In particular, when soy lecithin and batyl alcohol are combined, emulsification stability superior to other combinations can be exhibited.
- (E) component polyhydric alcohol
- the emulsion composition of this invention can aim at the further improvement of expression of emulsification power, such as polyglycerol fatty acid ester, by mix
- the polyhydric alcohol used here is not particularly limited, but specifically, ethylene glycol, diethylene glycol, polyethylene glycol, 1,3-butylene glycol, propylene glycol, dipropylene glycol, isoprene glycol, pentadiol.
- Divalent polyhydric alcohols such as glycerin (including concentrated glycerin) and the like, and polyglycerin having a polymerization degree of 2 to 10 (eg diglycerin, triglycerin, tetraglycerin etc.); sorbitol, multi Examples thereof include sugar alcohols such as tall and fructose. Glycerin is preferable.
- the polyhydric alcohol is blended so as to be contained in a proportion of 0.5 to 20% by weight, preferably 1 to 15% by weight, in 100% by weight of the final emulsified composition.
- the emulsified composition of the present invention when blended with a self-emulsifying glycerin fatty acid ester, provides electrolyte resistance to O / W emulsification and stabilizes the emulsion system. Can be achieved.
- Self-emulsifying type glycerin fatty acid ester has a nonionic surface active action in which glycerin fatty acid ester is dispersed in water by mixing hydrophilic surfactant such as fatty acid soap or polyethylene glycol fatty acid ester with glycerin fatty acid ester. Lipophilic emulsifier.
- the glycerin fatty acid ester is preferably composed of monoglycerin, specifically, self-emulsifying glyceryl monomyristate, self-emulsifying glyceryl monostearate, self-emulsifying Glyceryl monooleate and the like are suitable. More desirably, self-emulsifying glyceryl monostearate is used.
- the component (F) commercially available self-emulsifying glycerin fatty acid ester can be used as the component (F).
- the component (F) for example, Rheodor MS165V (manufactured by Kao Corporation); And NIKKOL MGS-ASEV (manufactured by Nikko Chemicals Co., Ltd.).
- these self-emulsifying glycerin fatty acid esters can be used alone or in any combination of two or more.
- the self-emulsifying glycerin fatty acid ester is blended so as to be contained in a proportion of 0.3 to 5% by weight, preferably in a proportion of 0.5 to 4% by weight, in 100% by weight of the final emulsified composition.
- the O / W type emulsion composition of the present invention contains the following components (G): moisture and (H) component: oil in predetermined amounts in addition to the components (A) to (F).
- the O / W emulsion composition of the present invention contains water, but water containing distilled water, ion-exchanged water, sterilized water, pure water or water containing adenosine phosphate as water. It can also be used. Examples of water containing such adenosine phosphate include seawater, hot spring water, mineral water, and the like. In addition, seawater does not ask the distinction of surface water, middle water, deep water, and super deep water here.
- the mixing ratio of such moisture in 100% by weight of the final emulsified composition is not particularly limited, but can be appropriately selected from the range of usually 30 to 80% by weight, preferably 40 to 70% by weight.
- Oil content used in the present invention is not particularly limited. Specifically, peanut oil, sesame oil, soybean oil, safflower oil, avocado oil, sunflower oil, corn oil, rapeseed oil, menziz oil, castor oil, coconut oil, coconut oil, olive oil, poppy oil, cacao oil, And vegetable oils such as jojoba oil, and fats and oils such as beef tallow, pork fat and wool oil; hydrocarbon liquid oils such as petrolatum, liquid paraffin, squalane, vegetable squalane, and ⁇ -olefin oligomers; myristin Isopropyl acid, isopropyl isostearate, myristyl myristate, cetyl palmitate, cetyl isooctanoate, isocetyl myristate, n-butyl myristate, octyldodecyl myristate, isopropyl linolenate, propyl ric
- oils can be used alone or in any combination of two or more. Such oil is preferably used in an amount of 1 to 40% by weight per 100% by weight of the final emulsified composition, more preferably 5 to 30% by weight, still more preferably 10 to 30% by weight. Can be mentioned.
- the emulsified composition of the present invention can be prepared by appropriately selecting from the compounds described as the components (A) to (H), but preferably, the following combinations are exemplified.
- Combination (iii) (A) Component adenosine monophosphate monosodium; (B) component decaglyceryl monomyristate, decaglyceryl monostearate; (C) component alkyl methacrylate methacrylate copolymer; (D) component stearic acid, behenyl alcohol; Component E) Concentrated glycerin; Component (F) Self-emulsifying glyceryl monostearate; Component (G) Pure water; Component (H) Liquid paraffin, tri (caprylic / capric acid) glyceryl, methylpolysiloxane.
- Combination (vii) (A) Component Adenosine-3 ', 5'-cyclic phosphoric acid; (B) Component decaglyceryl monostearate; (C) Component Alkyl methacrylate copolymer; (D) Component Batyl alcohol, stearic acid, behenyl alcohol Component (E) Concentrated glycerin; Component (F) Self-emulsifying glyceryl monomyristate; Component (G) Pure water; Component (H) Liquid paraffin, tri (caprylic / capric acid) glyceryl, methylpolysiloxane.
- composition for external use of the present invention is usually required to have a pH within a weakly acidic to neutral range, but it is preferable from the viewpoint of hypoallergenicity against skin and pigmentation improving effect.
- a pH adjuster can be blended in the external composition for skin.
- the pH adjuster to be blended in this way is not particularly limited as long as it is weakly alkaline to alkaline and pharmaceutically or cosmetically acceptable. Examples thereof include sodium hydroxide, potassium hydroxide, L-arginine, aminomethylpropanediol, diisopropanolamine, triethanolamine and the like.
- various surfactants, dyes (dyes, pigments), fragrances, preservatives, sterilizers may be used as necessary, as long as the effects of the present invention are not impaired.
- various additives such as agents, thickeners, antioxidants, sequestering agents, deodorants, etc., moisturizers, UV absorbers, UV scattering agents, vitamins, plant extracts, skin astringents, anti-inflammatory agents, whitening
- Various known ingredients such as agents, antioxidants, and cell activators, and in particular, known ingredients that are blended in external compositions applied to the skin, such as cosmetics and external pharmaceuticals and quasi drugs. Can do.
- the creamy O / W type emulsion composition of the present invention has a desired amount of adenosine phosphate, particularly 0.1% by weight or more, preferably 0.1 to 6% by weight, depending on the intended use and intended effect. Even if it is contained in a desired amount within the range, oil separation is significantly suppressed by long-term storage under conditions that are susceptible to temperature changes, and the emulsified state is stably maintained. Moreover, the cream-like O / W type emulsion composition of the present invention can be prepared so as not to be sticky depending on the intended use, and to have excellent skin feeling.
- the creamy O / W emulsion composition of the present invention is particularly useful as an external preparation such as cosmetics applied to the skin (including the scalp), pharmaceuticals for external use on the skin (including the scalp), and quasi drugs. is there.
- an external preparation such as cosmetics applied to the skin (including the scalp), pharmaceuticals for external use on the skin (including the scalp), and quasi drugs.
- adenosine monophosphate (AMP) or a salt thereof is used as adenosine phosphate ester
- cosmetics or skin excellent in moisturizing effect, prevention of drying and aging and improvement of rough skin based on the action of the AMP or salt thereof It can be prepared as an external preparation (pharmaceutical, quasi-drug).
- the cream O / W emulsion composition of the present invention can be prepared as an external preparation such as a cream cosmetic or a skin external preparation (pharmaceutical, quasi-drug).
- the form of the creamy external preparation is not particularly limited, and examples thereof include emollient cream, massage cream, cleansing cream, makeup cream and the like. These are applied and used on the skin in an appropriate amount / times or an appropriate number of times / day depending on the age, sex, application, degree of symptoms of the affected skin area, etc. of the user.
- the creamy O / W emulsion composition of the present invention comprises (A) 0.1% by weight or more of (A) adenosine phosphate ester and (B) 0.5-6 of polyglycerol fatty acid ester based on the total amount of the composition. % By weight, (C) 0.05 to 0.7% by weight of an alkyl methacrylate copolymer, (D) 0.5 to 10% by weight of an amphiphilic lipid, and (E) 0. 5 to 20% by weight and (F) self-emulsifying glycerin fatty acid ester is contained in an amount of 0.3 to 5% by weight, and its preparation method is not particularly limited, but it is prepared as follows. Preferably it is done.
- component polyglycerin fatty acid ester and (D) component: amphiphilic lipid, (E) component: polyhydric alcohol, (F) component: self-emulsifying glycerin fatty acid ester and (G) A mixture of components: oil is heated and stirred and dissolved uniformly to obtain a non-aqueous composition.
- a lower alcohol can be blended during cooling, thereby further promoting the percutaneous absorption of adenosine phosphate. can do.
- the lower alcohol used after mixing the non-aqueous emulsion and the aqueous solution is not particularly limited, and can be appropriately selected and used usually from alcohols having 1 to 6 carbon atoms, preferably ethanol, Examples thereof include alcohols having 1 to 4 carbon atoms such as propanol and isopropanol. These lower alcohols may be used alone or in any combination of two or more. More preferred is ethanol.
- the lower alcohol is blended so as to be contained in a proportion of 0.5 to 10% by weight, preferably 1 to 7% by weight, in 100% by weight of the final emulsified composition.
- the aqueous solution may be mixed with a polyhydric alcohol, whereby the moisture retention performance and sensory characteristics of the final emulsion composition can be adjusted to a desired level.
- a polyhydric alcohol those described above can be arbitrarily used.
- the polyhydric alcohol is the same as or highly compatible with the polyhydric alcohol. It is preferable to use it.
- the emulsification method of the non-aqueous composition and the aqueous solution (aqueous composition) can include a method of stirring under normal pressure or high pressure using a homomixer or the like, but the emulsion obtained as necessary Can be further refined using a homogenizer.
- the mixing ratio of the non-aqueous composition and the aqueous solution (aqueous composition) is not particularly limited, but the ratio of the non-aqueous emulsion per 100% by weight of the final emulsion composition is usually 1 to 40% by weight, preferably 5 to 35%. It is desirable to prepare it so that it may become a weight%, and this can manufacture a stable cream-like O / W type emulsion composition.
- the creamy O / W emulsion composition of the present invention is not particularly limited by its viscosity, but in the case of cosmetics, external medicines or external quasi-drugs applied to the skin, a B-type viscometer is usually used. , Rotor No. 4, viscosity measured at 20 rpm, 60000 cps or less, preferably 5000-60000 cps, more preferably 10,000-50000 cps, more preferably 15000-40000 cps, more preferably 15000-33000 cps, especially Preferably, it is prepared to be in the range of 20000-30000 cps.
- the viscosity of the creamy O / W emulsion composition of the present invention can be appropriately adjusted by blending the components (A) to (F) based on the blending ratio. For example, increasing the blending amount of component (C) or (D) tends to increase the viscosity, and increasing the blending amount of component (E) tends to decrease the viscosity. Therefore, the stability as an O / W emulsion composition can be maintained by appropriately adjusting the blending amounts of the components (A) to (F) within the above-mentioned blending ratio range in consideration of such characteristics. Meanwhile, a creamy O / W emulsion composition having a desired viscosity can be obtained.
- the viscosity of the creamy O / W emulsion composition of the present invention is within the above range, it is excellent in touch, has good elongation, and an excellent feeling in use can be obtained.
- Emulsification Stabilization Method for Cream O / W Emulsion Composition Containing Adenosine Phosphate Ester The present invention also provides an emulsion stabilization method for O / W emulsion composition containing adenosine phosphate ester.
- the method includes the above-mentioned alkyl methacrylate methacrylate copolymer, polyglycerin fatty acid ester, amphiphilic lipid, polyhydric alcohol and self-emulsifying glycerin fatty acid ester, moisture, oil content.
- Etc. can be used by preparing a creamy O / W emulsion composition.
- adenosine phosphate in 100% by weight of the final O / W emulsion composition, is 0.1% by weight or more, preferably 0.5 to 7% by weight, more preferably 1 to 6% by weight.
- Ratio 0.5 to 6% by weight of polyglycerin fatty acid ester, preferably 1 to 5.5% by weight; 0.05 to 0.7% by weight of alkyl methacrylic acid copolymer, 0.1 to Ratio of 0.6% by weight; ratio of amphiphilic lipid of 0.5 to 10% by weight, more preferably 0.5 to 5% by weight, still more preferably 0.5 to 3% by weight; 5 to 20% by weight, more preferably 1 to 15% by weight; and self-emulsifying glycerin fatty acid ester in a proportion of 0.3 to 5% by weight, preferably 0.5 to 4% by weight.
- the ratio of the oil contained in the final creamy O / W emulsion composition is not limited, but is preferably 1 to 40% by weight, more preferably 5 to 35% by weight, and still more preferably 10%. ⁇ 30% by weight.
- Moisture is a component that occupies the remainder other than the oil and other components, and is not particularly limited, but can be appropriately selected and adjusted usually within the range of 30 to 80% by weight, preferably 40 to 70% by weight. It is a ratio.
- the emulsion stabilization method of the present invention can be carried out by preparing a creamy O / W emulsion composition as described below so that each compounding component has the above-mentioned ratio. . 1) First, a mixture of polyglycerin fatty acid ester, amphiphilic lipid, oil, polyhydric alcohol and self-emulsifying glycerin fatty acid ester is heated and stirred, and uniformly dissolved to obtain a non-aqueous composition.
- an aqueous solution (aqueous composition) containing separately prepared adenosine phosphate, water and an alkyl methacrylate polymer is heated and mixed, and emulsified with the above non-aqueous composition at 60 to 80 ° C. To do. Then, it cools and a cream-like O / W type emulsion composition is prepared.
- emulsification stability can be imparted to a relatively high-viscosity dosage form, and long-term conditions under high temperature conditions or conditions subject to temperature changes can be obtained. Separation is significantly suppressed by storage, and an emulsified composition in which the emulsified state is stably maintained can be provided.
- Examples 1-8 Polyglycerin fatty acid ester, amphiphilic lipid, oil, polyhydric alcohol and self-emulsifying glycerin fatty acid ester were mixed and dissolved while heating to prepare a uniform non-aqueous composition.
- adenosine phosphate ester (adenosine monophosphate disodium, adenosine-3 ′, 5′-cyclic phosphate or sodium adenosine triphosphate), alkyl methacrylate methacrylate and pH
- An aqueous composition (aqueous solution) prepared by dissolving a regulator or the like in purified water (pure water) is added while heating, and the mixture is stirred and mixed at 80 ° C. with a homomixer. Thereafter, the emulsion compositions (Examples 1 to 8) of the present invention were prepared by cooling. Table 1 shows the composition of each component of the final composition.
- Examples 1 to 8 Eight kinds of prepared emulsion compositions (Examples 1 to 8) were each dispensed into three transparent glass bottles, and after the storage under the conditions (i) to (iii), the appearance properties (separated, Oil floatation and sudden viscosity drop) were visually confirmed and evaluated according to the following criteria. Conditions (i) to (iii) are as follows. (i) Stored at 40 ° C. for one month. (ii) Stored at 60 ° C. for 2 weeks. (iii) The cycle test at -5 to 40 ° C. (one cycle 24 hours) was repeated 15 times.
- This “separation” means a phenomenon in which an oil phase and an aqueous phase are separated into two phases due to deterioration of the emulsification system.
- Oil floating is also called creaming, and the oil strength is reduced due to a decrease in film strength at the oil-water interface. It means a phenomenon in which components in the phase become oil droplets and float on the liquid surface.
- the viscosity immediately after preparation was measured.
- the viscosity was measured using a B-type viscometer (BL model; manufactured by Tokyo Keiki Co., Ltd.) at rotor No. 4, rotation speed 6 rpm, and 20 ° C. The measurement results are shown in the table below.
- an emulsion composition containing no polyhydric alcohol as shown in Table 2 (Comparative Example 1) and a self-emulsifying monoglycerin fatty acid ester were used in the same manner as in Examples 1 to 8 above.
- Tables 1 and 2 show the results of storage stability tests on the emulsion compositions of Examples 1 to 8 and Comparative Examples 1 and 2, respectively.
- rhedol MS165V manufactured by Kao Corporation
- Pemulen TR-2 manufactured by Lubrizol
- monomyristic acid as glyceryl monostearate Polyglyceryl (manufactured by Nikko Chemicals Co., Ltd.) was used.
- the creamy O / W emulsion composition obtained as described above was excellent in stability over time and feeling in use.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
項1.乳化組成物の総量中に(A)~(F)成分を以下の割合で含み、20℃での粘度が5000~60000cpsであるクリーム状O/W型乳化組成物:
(A)アデノシン-3’,5’-環状リン酸、アデノシン一リン酸、アデノシン二リン酸、アデノシン三リン酸、及びこれらの塩からなる群より選択される少なくとも1種のアデノシンリン酸エステルを0.1重量%以上;
(B)ポリグリセリン脂肪酸エステルを0.5~6重量%;
(C)アクリル酸メタクリル酸アルキル共重合体を0.05~0.7重量%;
(D)両親媒性脂質を0.5~10重量%;
(E)多価アルコールを0.5~20重量%;及び
(F)自己乳化型グリセリン脂肪酸エステルを0.3~5重量%。
項2.(B)成分が、炭素数12~36の脂肪酸と重合度6以上のポリグリセリンとのエステルである項1に記載のクリーム状O/W型乳化組成物。
項3.(C)成分が、炭素数5~40のアルキル基を有するものである項1又は2に記載のクリーム状O/W型乳化組成物。
項4.(D)成分が、高級脂肪酸、高級アルコール、モノアルキルグリセリルエーテル、セラミド、糖セラミド、糖脂質、レシチン、レシチン誘導体、及びこれらの構造類似体からなる群より選択される少なくとも1種を含むことを特徴とする項1乃至3のいずれかに記載のクリーム状O/W型乳化組成物。
項5.(E)成分が、3価の多価アルコールである項1乃至4のいずれかに記載のクリーム状O/W型乳化組成物。
項6.(F)成分が、親水性界面活性剤を混合して親水性を高くした自己乳化型グリセリン脂肪酸エステルである項1乃至5のいずれかに記載のクリーム状O/W型乳化組成物。
項7.さらに、(G)水分を30~80重量%含む項1乃至6に記載のクリーム状O/W型乳化組成物。
項8.さらに、(H)油分を1~40重量%含む項1乃至7に記載のクリーム状O/W型乳化組成物。
項9.皮膚化粧料または皮膚外用医薬品若しくは医薬部外品である項1乃至8のいずれかに記載のクリーム状O/W型乳化組成物。
項10.項1乃至8のいずれかに記載のクリーム状O/W型乳化組成物の皮膚化粧料、皮膚医薬品または皮膚外用医薬部外品の製造のための使用。
項11.下記の工程1)~3)を含み、組成物全量に対して(A)アデノシンリン酸エステルを0.1重量%以上、(B)ポリグリセリン脂肪酸エステルを0.5~6重量%、(C)アクリル酸メタクリル酸アルキル共重合体が0.05~0.7重量%、(D)両親媒性脂質が0.5~10重量%、(E)多価アルコールが0.5~20重量%、及び(F)自己乳化型グリセリン脂肪酸エステルが0.3~5重量%の割合で含まれ、20℃での粘度が5000~60000cpsであることを特徴とする、クリーム状O/W型乳化組成物の調製方法:
1)(B)ポリグリセリン脂肪酸エステル、(D)両親媒性脂質、(E)多価アルコール及び(F)自己乳化型グリセリン脂肪酸エステルを含む組成物を用いて非水乳化物を調製する工程、
2)(A)アデノシン-3’,5’-環状リン酸、アデノシン一リン酸、アデノシン二リン酸、アデノシン三リン酸、及びこれらの塩からなる群より選択される少なくとも1種のアデノシンリン酸エステル、及び(C)アクリル酸メタクリル酸アルキル共重合体を含む水溶液を調製する工程、ならびに
3)上記非水乳化物と水溶液を加温混合する工程。
項12.下記の工程1)~3)を含み、組成物全量に対して(A)アデノシンリン酸エステルを0.1重量%以上、(B)ポリグリセリン脂肪酸エステルを0.5~6重量%、(C)アクリル酸メタクリル酸アルキル共重合体が0.05~0.7重量%、(D)両親媒性脂質が0.5~10重量%、(E)多価アルコールが0.5~20重量%、及び(F)自己乳化型グリセリン脂肪酸エステルが0.3~5重量%の割合で含まれ、20℃での粘度が5000~60000cpsであることを特徴とする、アデノシンリン酸エステルを含有するクリーム状O/W型乳化組成物の乳化安定方法:
1)(B)ポリグリセリン脂肪酸エステル、(D)両親媒性脂質、(E)多価アルコール及び(F)自己乳化型グリセリン脂肪酸エステルを含む組成物を用いて非水乳化物を調製する工程、
2)(A)アデノシン-3’,5’-環状リン酸、アデノシン一リン酸、アデノシン二リン酸、アデノシン三リン酸、及びこれらの塩からなる群より選択される少なくとも1種のアデノシンリン酸エステル、及び(C)アクリル酸メタクリル酸アルキル共重合体を含む水溶液を調製する工程、ならびに
3)上記非水乳化物と水溶液を加温混合して乳化する工程。
本発明のクリーム状O/W型乳化組成物は、所定量の下記(A)~(F)成分を含むことを特徴とする。以下、本発明の構成について詳述する。
本発明で用いられるアデノシンリン酸エステルは、特に限定されないが、好ましくは皮膚に適用されて生理機能を発揮するものであって、例えば外用剤、特に化粧品や外用の医薬品又は医薬部外品中に配合できるものを広く挙げることができる。好ましくは水溶性若しくは親水性のものである。
本発明で用いられるポリグリセリン脂肪酸エステルとしては、特に特定されないが、炭素数が12~36の脂肪酸と重合度が6以上、特に6~10のポリグリセリンとのエステルを挙げることができる。ポリグリセリンとエステルを形成する脂肪酸は飽和、不飽和、直鎖状又は分枝鎖状のいずれの脂肪酸でも良く、具体的にはカプリン酸、ラウリン酸、イソトリデカン酸、ミリスチン酸、パルミチン酸、パルミトレイン酸、ステアリン酸、イソステアリン酸、オレイン酸、リノール酸、ベヘニン酸またはリシノール酸などを例示することができる。
本発明で用いられるアクリル酸メタクリル酸アルキル重合体としては、特に制限されるものではないが、通常はアルキル鎖の炭素数が5~40のものを挙げることができる。好ましくは、アルキル鎖の炭素数が10~30のものである。これらは簡便には商業的に入手できるものを利用することができ、制限されないが、具体的にはCarbopol(商標) 1342(ルーブリゾール社製)、Carbopol(商標) ETD2020(ルーブリゾール社製)、Pemulen(商標) TR-1(ルーブリゾール社製)、Pemulen TR-2(ルーブリゾール社製)等を例示することができる。
両親媒性脂質は、1つの分子内に「親水基」(親水性官能基)と「親油基」(疎水性官能基)を併せ持ち、水には溶解しないが分散する傾向にある固形の脂質の総称である。
本発明の乳化組成物は、多価アルコールを配合することによって、ポリグリセリン脂肪酸エステル等の乳化力の発現の一層の向上を図ることができる。
本発明の乳化組成物は、自己乳化型グリセリン脂肪酸エステルを配合することによって、O/W型乳化に対して耐電解質性をもたらし、乳化系の安定化を図ることができる。自己乳化型グリセリン脂肪酸エステルは、脂肪酸石けんやポリエチレングリコール脂肪酸エステルなどの親水性界面活性剤とグリセリン脂肪酸エステルとを混合し、グリセリン脂肪酸エステルを水に分散するようにした非イオン性界面活性作用を有する親油性乳化剤である。ここで用いられる自己乳化型グリセリン脂肪酸エステルにおいて、グリセリン脂肪酸エステルはモノグリセリンで構成されるものが望ましく、具体的には、自己乳化型モノミリスチン酸グリセリル、自己乳化型モノステアリン酸グリセリル、自己乳化型モノオレイン酸グリセリルなどが好適である。さらに望ましくは、自己乳化型モノステアリン酸グリセリルを用いることが好適である。
また本発明のO/W型乳化組成物は、水分を含有するが、水分として蒸留水、イオン交換水、滅菌水、純水のほか、アデノシンリン酸エステルを含む水を用いることもできる。かかるアデノシンリン酸エステルを含む水としては、例えば、海水、温泉水、ミネラル水などを例示することができる。なお、ここで海水とは表層水、中層水、深層水、超深層水の別を問うものではない。
本発明で使用される油分は特に限定されるものではない。具体的には、ラッカセイ油、ゴマ油、大豆油、サフラワー油、アボガド油、ヒマワリ油、トウモロコシ油、菜種油、メンジツ油、ヒマシ油、椿油、ヤシ油、オリ-ブ油、ケシ油、カカオ油、及びホホバ油等の植物油、並びに牛脂、豚脂、及び羊毛油等の動物油脂などの油脂類;ワセリン、流動パラフィン、スクワラン、植物性スクワラン、及びα-オレフィンオリゴマー等の炭化水素系液状油;ミリスチン酸イソプロピル、イソステアリン酸イソプロピル、ミリスチン酸ミリスチル、パルミチン酸セチル、イソオクタン酸セチル、ミリスチン酸イソセチル、ミリスチン酸n-ブチル、ミリスチン酸オクチルドデシル、リノレン酸イソプロピル、リシノール酸プロピル、リシノール酸イソプロピル、リシノール酸イソブチル、リシノール酸ヘプチル、セバシン酸ジエチル、及びアジピン酸ジイソプロピル等の高級脂肪酸エステル;サラシミツロウ、鯨ロウ、及び木ロウ等のロウ類;マイクロクリスタリンワックス、パラフィンワックス等のワックス類;アセトグリセリル、トリイソオクタン酸グリセリル、トリイソステアリン酸グリセリル、トリイソパルミチン酸グリセリル、トリ-2-エチルヘキサン酸グリセリル、モノステアリン酸グリセリル、ジベヘン酸グリセリル、トリミリスチン酸グリセリル、トリ(カプリル・カプリン酸)グリセリル、炭素数12~18の飽和又は不飽和脂肪酸のモノ、ジ、トリグリセリル混合物などのグリセリル油類;メチルポリシロキサン,ジメチルポリシロキサン,メチルフェニルポリシロキサン,メチルハイドロゲンポリシロキサンなどの鎖状シリコーン、デカメチルシクロペンタシロキサン,オクタメチルシクロテトラシロキサン,メチルシクロシロキサンなどの環状シリコーン、架橋型メチルポリシロキサン及び架橋型メチルフェニルポリシロキサン等の架橋型シリコーン、例えばポリオキシエチレンやポリオキシプロピレン等で変性した変性シリコーンなどのシリコーン油などを例示できる。
(A)成分 アデノシン一リン酸二ナトリウム;(B)成分 モノステアリン酸デカグリセリル;(C)成分 アクリル酸メタクリル酸アルキル共重合体;(D)成分 セチルアルコール,水素添加大豆リン脂質, ステアリン酸,ベヘニルアルコール;(E)成分 濃グリセリン,ジプロピレングリコール;(F)成分 自己乳化型モノステアリン酸グリセリル;(G)成分 純水;(H)成分 トリ(カプリル・カプリン酸)グリセリル,メチルポリシロキサン。
(A)成分 アデノシン一リン酸二ナトリウム;(B)成分 モノミリスチン酸デカグリセリル;(C)成分 アクリル酸メタクリル酸アルキル共重合体;(D)成分 ステアリン酸,ベヘニルアルコール;(E)成分 濃グリセリン,ジプロピレングリコール;(F)成分 自己乳化型モノオレイン酸グリセリル;(G)成分 純水;(H)成分 流動パラフィン,トリ(カプリル・カプリン酸)グリセリル,メチルポリシロキサン。
(A)成分 アデノシン一リン酸一ナトリウム;(B)成分 モノミリスチン酸デカグリセリル,モノステアリン酸デカグリセリル;(C)成分 アクリル酸メタクリル酸アルキル共重合体;(D)成分 ステアリン酸,ベヘニルアルコール;(E)成分 濃グリセリン;(F)成分 自己乳化型モノステアリン酸グリセリル;(G)成分 純水;(H)成分 流動パラフィン,トリ(カプリル・カプリン酸)グリセリル,メチルポリシロキサン。
(A)成分 アデノシン三リン酸一ナトリウム;(B)成分 モノミリスチン酸デカグリセリル;(C)成分 アクリル酸メタクリル酸アルキル共重合体;(D)成分 バチルアルコール,水素添加大豆リン脂質,ステアリン酸,ベヘニルアルコール;(E)成分 濃グリセリン;(F)成分 自己乳化型モノステアリン酸グリセリル;(G)成分 純水;(H)成分 流動パラフィン,トリ(カプリル・カプリン酸)グリセリル,メチルポリシロキサン。
(A)成分 アデノシン三リン酸ニナトリウム;(B)成分 モノステアリン酸デカグリセリル;(C)成分 アクリル酸メタクリル酸アルキル共重合体;(D)成分 コレステロール,ステアリン酸,ベヘニルアルコール;(E)成分 濃グリセリン,ジプロピレングリコール;(F)成分 自己乳化型モノオレイン酸グリセリル;(G)成分 純水;(H)成分 流動パラフィン,トリ(カプリル・カプリン酸)グリセリル,メチルポリシロキサン。
(A)成分 アデノシン三リン酸三ナトリウム;(B)成分 モノミリスチン酸デカグリセリル;(C)成分 アクリル酸メタクリル酸アルキル共重合体;(D)成分 ステアリン酸,ベヘニルアルコール;(E)成分 濃グリセリン;(F)成分 自己乳化型モノステアリン酸グリセリル;(G)成分 純水;(H)成分 トリ(カプリル・カプリン酸)グリセリル,メチルポリシロキサン 。
(A)成分 アデノシン-3’,5’-環状リン酸;(B)成分 モノステアリン酸デカグリセリル;(C)成分 アクリル酸メタクリル酸アルキル共重合体;(D)成分 バチルアルコール,ステアリン酸,ベヘニルアルコール;(E)成分 濃グリセリン;(F)成分 自己乳化型モノミリスチン酸グリセリル;(G)成分 純水;(H)成分 流動パラフィン,トリ(カプリル・カプリン酸)グリセリル,メチルポリシロキサン。
(A)成分 リン酸アデノシン;(B)成分 モノミリスチン酸デカグリセリル;(C)成分 アクリル酸メタクリル酸アルキル共重合体;(D)成分 水素添加大豆リン脂質,コレステロール,ステアリン酸,ベヘニルアルコール;(E)成分 濃グリセリン,ジプロピレングリコール;(F)成分 ステアリル自己乳化型モノステアリン酸グリセリル;(G)成分 純水;(H)成分 流動パラフィン、トリ(カプリル・カプリン酸)グリセリル,メチルポリシロキサン。
本発明の外用組成物は、通常弱酸性~中性の範囲内のpHを備えていればよいが、皮膚に対する低刺激性、及び色素沈着改善効果の点からは、好ましくはpH5~7、更に好ましくはpH5.5~7である。本発明の外用組成物のpHを上記範囲に調整するために、該皮膚外用組成物にpH調整剤を配合することができる。このように配合されるpH調整剤としては、弱アルカリ性~アルカリ性であって薬学的或いは香粧的に許容されるものであれば特に制限されない。一例として、水酸化ナトリウム、水酸化カリウム、L-アルギニン、アミノメチルプロパンジオール、ジイソプロパノールアミン、トリエタノールアミン等を挙げることができる。
本発明のクリーム状O/W型乳化組成物は、組成物全量に対して(A)アデノシンリン酸エステルを0.1重量%以上、(B)ポリグリセリン脂肪酸エステルを0.5~6重量%、(C)アクリル酸メタクリル酸アルキル共重合体が0.05~0.7重量%、(D)両親媒性脂質が0.5~10重量%、(E)多価アルコールが0.5~20重量%、及び(F)自己乳化型グリセリン脂肪酸エステルが0.3~5重量%含まれることを特徴とするものであり、その調製方法は特に制限されないが、下記のようにして調製されるのが好ましい。
1)まず、前述する(B)成分:ポリグリセリン脂肪酸エステルと (D)成分:両親媒性脂質、(E)成分:多価アルコール、 (F)成分:自己乳化型グリセリン脂肪酸エステル及び(G)成分:油分、の混合物を、加温撹拌し、均一に溶解して非水系組成物を得る。
2)次いで、別個に調製した(A)成分:アデノシンリン酸エステル、(C)成分:アクリル酸メタクリル酸アルキル重合体及び(H)成分:水分を含有する水溶液(水系組成物)を加温混合して上記非水乳化物と60~80℃で乳化する。その後、冷却してクリーム状O/W型乳化組成物を調製する。
本発明は、またアデノシンリン酸エステルを含有するO/W型乳化組成物の乳化安定方法を提供する。当該方法は、前述するアデノシンリン酸エステルに加えて、前述するアクリル酸メタクリル酸アルキル共重合体、ポリグリセリン脂肪酸エステル、両親媒性物脂質、多価アルコール及び自己乳化型グリセリン脂肪酸エステル、水分、油分等を用いて、クリーム状O/W型乳化組成物を調製することによって実施することができる。
1)まず、ポリグリセリン脂肪酸エステル、両親媒性脂質、油分、多価アルコール及び自己乳化型グリセリン脂肪酸エステルの混合物を、加温撹拌し、均一に溶解して非水系組成物を得る。
2)次いで、別個に調製したアデノシンリン酸エステル、水分及びアクリル酸メタクリル酸アルキル重合体を含有する水溶液(水系組成物)を加温混合して、上記非水系組成物と60~80℃で乳化する。その後、冷却してクリーム状O/W型乳化組成物を調製する。
ポリグリセリン脂肪酸エステル、両親媒性脂質、油分、多価アルコール及び自己乳化型グリセリン脂肪酸エステルを混合して、加温しながら溶解して均一な非水系組成物を調製した。この非水系組成物に、別途、アデノシンリン酸エステル(アデノシン一リン酸二ナトリウム、アデノシン-3’,5’-環状リン酸又はアデノシン三リン酸ナトリウム)、アクリル酸メタクリル酸アルキル共重合体及びpH調整剤等を精製水(純水)に溶解して調製しておいた水系組成物(水溶液)を加温しながら加え、80℃にてホモミキサーで撹拌混合する。その後、冷却することによって本発明の乳化組成物(実施例1~8)を作成した。最終組成物の各成分組成を表1に示す。
(i)40℃で1箇月保管した。
(ii)60℃で2週間保管した。
(iii)-5~40℃でのサイクル試験(1サイクル24時間)を15回繰り返した。
良好:分離、油浮き及び急激な粘性低下のいずれも認めない。
不良:分離、油浮きまたは急激な粘性低下のいずれかを認める。
なお、自己乳化型モノステアリン酸グリセリルとしてレオドールMS165V(花王株式会社製);アクリル酸メタクリル酸アルキル共重合体としてPemulen TR-2(ルーブリゾール社製);親油型モノステアリン酸グリセリルとしてモノミリスチン酸ポリグリセリル(日光ケミカルズ株式会社製)を用いた。
上記実施例の方法に従って、下記表3に示される組成のO/W型乳化組成物を調製した。単位は、最終乳化組成物100重量%中の割合を示す。
Claims (12)
- 乳化組成物の総量中に(A)~(F)成分を以下の割合で含み、20℃での粘度が5000~60000cpsであるクリーム状O/W型乳化組成物:
(A)アデノシン-3’,5’-環状リン酸、アデノシン一リン酸、アデノシン二リン酸、アデノシン三リン酸、及びこれらの塩からなる群より選択される少なくとも1種のアデノシンリン酸エステルを0.1重量%以上;
(B)ポリグリセリン脂肪酸エステルを0.5~6重量%;
(C)アクリル酸メタクリル酸アルキル共重合体を0.05~0.7重量%;
(D)両親媒性脂質を0.5~10重量%;
(E)多価アルコールを0.5~20重量%;及び
(F)自己乳化型グリセリン脂肪酸エステルを0.3~5重量%。 - (B)成分が、炭素数12~36の脂肪酸と重合度6以上のポリグリセリンとのエステルである請求項1に記載のクリーム状O/W型乳化組成物。
- (C)成分が、炭素数5~40のアルキル基を有するものである請求項1又は2に記載のクリーム状O/W型乳化組成物。
- (D)成分が、高級脂肪酸、高級アルコール、モノアルキルグリセリルエーテル、セラミド、糖セラミド、糖脂質、レシチン、レシチン誘導体、及びこれらの構造類似体からなる群より選択される少なくとも1種を含むことを特徴とする請求項1乃至3のいずれかに記載のクリーム状O/W型乳化組成物。
- (E)成分が、3価の多価アルコールである請求項1乃至4のいずれかに記載のクリーム状O/W型乳化組成物。
- (F)成分が、親水性界面活性剤を混合して親水性を高くした自己乳化型グリセリン脂肪酸エステルである請求項1乃至5のいずれかに記載のクリーム状O/W型乳化組成物。
- さらに、(G)水分を30~80重量%含む請求項1乃至6のいずれかに記載のクリーム状O/W型乳化組成物。
- さらに、(H)油分を1~40重量%含む請求項1乃至7のいずれかに記載のクリーム状O/W型乳化組成物。
- 皮膚化粧料または皮膚外用医薬品若しくは医薬部外品である請求項1乃至8のいずれかに記載のクリーム状O/W型乳化組成物。
- 請求項1乃至8のいずれかに記載のクリーム状O/W型乳化組成物の皮膚化粧料、皮膚医薬品または皮膚外用医薬部外品の製造のための使用。
- 下記の工程1)~3)を含み、組成物全量に対して(A)アデノシンリン酸エステルを0.1重量%以上、(B)ポリグリセリン脂肪酸エステルを0.5~6重量%、(C)アクリル酸メタクリル酸アルキル共重合体が0.05~0.7重量%、(D)両親媒性脂質が0.5~10重量%、(E)多価アルコールが0.5~20重量%、及び(F)自己乳化型グリセリン脂肪酸エステルが0.3~5重量%の割合で含まれ、20℃での粘度が5000~60000cpsであることを特徴とする、クリーム状O/W型乳化組成物の調製方法:
1)(B)ポリグリセリン脂肪酸エステル、(D)両親媒性脂質、(E)多価アルコール及び(F)自己乳化型グリセリン脂肪酸エステルを含む組成物を用いて非水乳化物を調製する工程、
2)(A)アデノシン-3’,5’-環状リン酸、アデノシン一リン酸、アデノシン二リン酸、アデノシン三リン酸、及びこれらの塩からなる群より選択される少なくとも1種のアデノシンリン酸エステル、及び(C)アクリル酸メタクリル酸アルキル共重合体を含む水溶液を調製する工程、ならびに
3)上記非水乳化物と水溶液を加温混合して乳化する工程。 - 下記の工程1)~3)を含み、組成物全量に対して(A)アデノシンリン酸エステルを0.1重量%以上、(B)ポリグリセリン脂肪酸エステルを0.5~6重量%、(C)アクリル酸メタクリル酸アルキル共重合体が0.05~0.7重量%、(D)両親媒性脂質が0.5~10重量%、(E)多価アルコールが0.5~20重量%、及び(F)自己乳化型グリセリン脂肪酸エステルが0.3~5重量%の割合で含まれ、20℃での粘度が5000~60000cpsであることを特徴とする、アデノシンリン酸エステルを含有するクリーム状O/W型乳化組成物の乳化安定方法:
1)(B)ポリグリセリン脂肪酸エステル、(D)両親媒性脂質、(E)多価アルコール及び(F)自己乳化型グリセリン脂肪酸エステルを含む組成物を用いて非水乳化物を調製する工程、
2)(A)アデノシン-3’,5’-環状リン酸、アデノシン一リン酸、アデノシン二リン酸、アデノシン三リン酸、及びこれらの塩からなる群より選択される少なくとも1種のアデノシンリン酸エステル、及び(C)アクリル酸メタクリル酸アルキル共重合体を含む水溶液を調製する工程、ならびに
3)上記非水乳化物と水溶液を加温混合して乳化する工程。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2726890A CA2726890C (en) | 2008-06-03 | 2009-06-02 | Creamy o/w emulsion composition and production process thereof |
JP2010515879A JP4698765B2 (ja) | 2008-06-03 | 2009-06-02 | クリーム状o/w型乳化組成物及びその製造方法 |
ES09758326.4T ES2567044T3 (es) | 2008-06-03 | 2009-06-02 | Composición cremosa de emulsión de aceite en agua y procedimiento de producción de la misma |
EP09758326.4A EP2301555B1 (en) | 2008-06-03 | 2009-06-02 | Creamy o/w emulsion composition and production process thereof |
CN2009801205881A CN102046184B (zh) | 2008-06-03 | 2009-06-02 | 乳脂状o/w型乳化组合物及其制造方法 |
US12/995,894 US8492360B2 (en) | 2008-06-03 | 2009-06-02 | Creamy O/W emulsion composition and production process thereof |
HK11108944.7A HK1154779A1 (zh) | 2008-06-03 | 2011-08-24 | 乳脂狀 型乳化組合物及其製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-146104 | 2008-06-03 | ||
JP2008146104 | 2008-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009148059A1 true WO2009148059A1 (ja) | 2009-12-10 |
Family
ID=41398133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/060086 WO2009148059A1 (ja) | 2008-06-03 | 2009-06-02 | クリーム状o/w型乳化組成物及びその製造方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8492360B2 (ja) |
EP (1) | EP2301555B1 (ja) |
JP (1) | JP4698765B2 (ja) |
KR (1) | KR101154693B1 (ja) |
CN (1) | CN102046184B (ja) |
CA (1) | CA2726890C (ja) |
ES (1) | ES2567044T3 (ja) |
HK (1) | HK1154779A1 (ja) |
TW (1) | TWI445554B (ja) |
WO (1) | WO2009148059A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018016587A (ja) * | 2016-07-28 | 2018-02-01 | アサヌマ コーポレーション株式会社 | 水中油型メイクアップ化粧料 |
WO2019151275A1 (ja) * | 2018-01-31 | 2019-08-08 | 大塚製薬株式会社 | アデノシンリン酸含有組成物のべたつき改善方法 |
JP2019140983A (ja) * | 2018-02-21 | 2019-08-29 | 丸大食品株式会社 | 乳化組成物製造方法 |
JP2020122027A (ja) * | 2016-07-28 | 2020-08-13 | アサヌマ コーポレーション株式会社 | 水中油型メイクアップ化粧料 |
WO2020217503A1 (ja) * | 2019-04-26 | 2020-10-29 | 大塚製薬株式会社 | アデノシンリン酸を含有するo/w型高粘度乳化組成物 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013228828B2 (en) * | 2012-03-05 | 2017-10-26 | Otsuka Pharmaceutical Co., Ltd. | Sunscreen composition |
DE102014104258A1 (de) * | 2014-03-26 | 2015-10-01 | Beiersdorf Ag | Wirkstoffkombinationen aus 4-Hydroxyacetophenon und einem oder mehreren Glycerin- und/oder Oligoglycerinester von verzweigtkettigen und/oder unverzweigtkettigen Alkancarbonsäuren, sowie kosmetische oder dermatologische Zubereitungen, diese Wirkstoffkombinationen enthaltend |
WO2017027707A1 (en) * | 2015-08-13 | 2017-02-16 | Sense Technology, Inc. | Neurochemical lotion to support manual therapy |
KR102067055B1 (ko) * | 2015-11-27 | 2020-01-17 | (주)아모레퍼시픽 | 세라마이드를 포함하는 유화 화장료 조성물 및 그 제조방법 |
WO2020217499A1 (ja) * | 2019-04-26 | 2020-10-29 | 大塚製薬株式会社 | アデノシンリン酸を含有するo/w型低粘度乳化組成物 |
US20220354868A1 (en) * | 2019-06-27 | 2022-11-10 | Kao Corporation | External preparation for skin |
JP2024503463A (ja) * | 2021-01-13 | 2024-01-25 | ダイブ バイオサイエンシーズ,インク. | 薬剤投与用の経皮浸透製剤 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55141174A (en) * | 1979-04-19 | 1980-11-04 | Taiyo Yushi Kk | Method of making synthetic cream for whip |
JPH07126191A (ja) * | 1993-10-27 | 1995-05-16 | Taisho Pharmaceut Co Ltd | クリーム剤 |
JP2002234830A (ja) | 2000-11-22 | 2002-08-23 | Otsuka Pharmaceut Co Ltd | O/w型乳化組成物及びその調製方法 |
JP2004513068A (ja) * | 2000-05-12 | 2004-04-30 | アルウィン カンパニー, インコーポレイテッド | アラントイン含有皮膚クリーム |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0115582A (pt) | 2000-11-22 | 2004-01-06 | Otsuka Pharma Co Ltd | Composição de emulsão de o/a e método para a preparação da mesma |
AU2003234818B8 (en) * | 2002-05-20 | 2009-03-26 | Otsuka Pharmaceutical Co., Ltd. | Chloasma amelioration composition and dullness amelioration composition |
US20090285876A1 (en) * | 2008-05-14 | 2009-11-19 | Hein Arthur J | Natural butters reconstituted by transesterification with glycerin and its use in cosmetics applications |
-
2009
- 2009-06-02 CN CN2009801205881A patent/CN102046184B/zh active Active
- 2009-06-02 ES ES09758326.4T patent/ES2567044T3/es active Active
- 2009-06-02 JP JP2010515879A patent/JP4698765B2/ja active Active
- 2009-06-02 EP EP09758326.4A patent/EP2301555B1/en active Active
- 2009-06-02 CA CA2726890A patent/CA2726890C/en not_active Expired - Fee Related
- 2009-06-02 KR KR1020107029861A patent/KR101154693B1/ko active IP Right Grant
- 2009-06-02 WO PCT/JP2009/060086 patent/WO2009148059A1/ja active Application Filing
- 2009-06-02 US US12/995,894 patent/US8492360B2/en active Active
- 2009-06-03 TW TW098118362A patent/TWI445554B/zh active
-
2011
- 2011-08-24 HK HK11108944.7A patent/HK1154779A1/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55141174A (en) * | 1979-04-19 | 1980-11-04 | Taiyo Yushi Kk | Method of making synthetic cream for whip |
JPH07126191A (ja) * | 1993-10-27 | 1995-05-16 | Taisho Pharmaceut Co Ltd | クリーム剤 |
JP2004513068A (ja) * | 2000-05-12 | 2004-04-30 | アルウィン カンパニー, インコーポレイテッド | アラントイン含有皮膚クリーム |
JP2002234830A (ja) | 2000-11-22 | 2002-08-23 | Otsuka Pharmaceut Co Ltd | O/w型乳化組成物及びその調製方法 |
Non-Patent Citations (2)
Title |
---|
NIPPON IYAKUHIN TENKABUTSU KYOKAI: "Iyakuhin Tenkabutsu Jiten", 14 January 1994, pages: 184, 191, XP008142247 * |
See also references of EP2301555A4 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018016587A (ja) * | 2016-07-28 | 2018-02-01 | アサヌマ コーポレーション株式会社 | 水中油型メイクアップ化粧料 |
JP2020122027A (ja) * | 2016-07-28 | 2020-08-13 | アサヌマ コーポレーション株式会社 | 水中油型メイクアップ化粧料 |
WO2019151275A1 (ja) * | 2018-01-31 | 2019-08-08 | 大塚製薬株式会社 | アデノシンリン酸含有組成物のべたつき改善方法 |
JP2019140983A (ja) * | 2018-02-21 | 2019-08-29 | 丸大食品株式会社 | 乳化組成物製造方法 |
WO2020217503A1 (ja) * | 2019-04-26 | 2020-10-29 | 大塚製薬株式会社 | アデノシンリン酸を含有するo/w型高粘度乳化組成物 |
WO2020218547A1 (ja) * | 2019-04-26 | 2020-10-29 | 大塚製薬株式会社 | アデノシンリン酸を含有するo/w型高粘度乳化組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN102046184A (zh) | 2011-05-04 |
US20110112045A1 (en) | 2011-05-12 |
CN102046184B (zh) | 2013-05-08 |
TW201008597A (en) | 2010-03-01 |
ES2567044T3 (es) | 2016-04-19 |
KR101154693B1 (ko) | 2012-06-08 |
JP4698765B2 (ja) | 2011-06-08 |
EP2301555A4 (en) | 2011-06-22 |
JPWO2009148059A1 (ja) | 2011-10-27 |
TWI445554B (zh) | 2014-07-21 |
EP2301555A1 (en) | 2011-03-30 |
HK1154779A1 (zh) | 2012-05-04 |
KR20110028319A (ko) | 2011-03-17 |
CA2726890C (en) | 2015-08-04 |
US8492360B2 (en) | 2013-07-23 |
EP2301555B1 (en) | 2016-02-17 |
CA2726890A1 (en) | 2009-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4698765B2 (ja) | クリーム状o/w型乳化組成物及びその製造方法 | |
EP1342462B1 (en) | O/w emulsion composition and method of preparing the same | |
JP4425127B2 (ja) | 肝斑改善用組成物及びくすみ改善用組成物 | |
JP6426363B2 (ja) | 水中油型乳化組成物 | |
JP3994257B2 (ja) | O/w型乳化組成物及びその調製方法 | |
JP2013001698A (ja) | 油性ゲル状クレンジング用組成物 | |
KR102104095B1 (ko) | 유화 화장료 | |
JP4164683B2 (ja) | O/w型乳化組成物及びその調製方法 | |
JP2009234972A (ja) | 乳化化粧料 | |
JP2013082643A (ja) | O/w型エマルジョン | |
JP5956138B2 (ja) | 水中油型乳化組成物 | |
JP2748962B2 (ja) | 親水性ゲル状組成物および水中油型乳化組成物 | |
KR102104096B1 (ko) | 유화 화장료 | |
WO2023106121A1 (ja) | 水中油型乳化化粧料 | |
JP2023069593A (ja) | 水中油型乳化組成物 | |
JP2022151456A (ja) | 皮膚用組成物 | |
JP2021011459A (ja) | 乳化化粧料組成物 | |
JP2019038756A (ja) | 新規親水性基剤中油型乳化組成物 | |
WO2014141948A1 (ja) | 乳液状化粧料組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980120588.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09758326 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2010515879 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12995894 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2726890 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009758326 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107029861 Country of ref document: KR Kind code of ref document: A |